Tirzepatide’s two-receptor effect
Tirzepatide activates both the GLP-1 and GIP receptors, which is part of why its titration schedule is more forgiving than some single-receptor GLP-1 drugs. Even so, moving too fast between steps still brings on nausea and reduced appetite hard enough that most people slow down rather than push through it.
The published step pattern
Zepbound and Mounjaro’s approved schedule starts at 2.5mg for four weeks, purely to let the body adjust, since 2.5mg isn’t considered a fully effective dose on its own. From there it steps up to 5mg, then in 2.5mg increments up to a maximum of 15mg, each step held for at least four weeks.
What each step changes
Appetite suppression and slower gastric emptying both get stronger with each increase. That’s also why constipation, not just nausea, becomes more commonly reported at higher steps; food spends longer in the gut at every stage of digestion.
Comparing the pace with retatrutide
Retatrutide’s published schedules generally use a similar four-week hold, but with a triple-receptor effect (GLP-1, GIP and glucagon) that some people report as a stronger initial adjustment period. Neither schedule is objectively “gentler”; the difference shows up person to person.
Reading a UK tirzepatide listing
A dosing chart attached to a listing should show the same broad shape described here: low start, gradual increments, month-long holds. If a chart skips straight from a starting dose to a high maintenance dose in two steps, treat it as unverified rather than assuming it’s a faster protocol.